Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1935]

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

Professor Martin Wermke - National Center for Tumor Diseases, Dresden, Germany

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC ( Professor Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder...

Prof Andrea Necchi - Vita-Salute San Raffaele University, Milan, Italy

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer ( Prof Andrea Necchi - Vita-Salute San Raffaele University, Milan, Italy )

ESMO 2025: Bladder cancer highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Bladder cancer highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2025: Renal highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Renal highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

Durvalumab with BCG and maintenance therapy improves disease-free survival in...

Dr Maria De Santis - Charité University Hospital, Berlin, Germany

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC ( Dr Maria De Santis - Charité University Hospital, Berlin, Germany )

Perioperative enfortumab vedotin plus pembro improves survival and pCR in...

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine...

Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh...

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer ( Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in...

Prof Martin Schuler - Essen University Hospital, Essen, Germany

Improving efficacy and toxicity reporting - and treatment insights from an...

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

More from ecancer